よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (93 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
74. Shields RK, et al. Effectiveness of ceftazidime-avibactam versus ceftolozanetazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA
(CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025.
25(5):574-584.
5
6
7
75. Hareza DA, et al. Clinical outcomes and emergence of resistance of Pseudomonas
aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidimeavibactam. Antimicrob Agents Chemother. 2024. 68(10):e0090724.
8
9
10
76. Almangour TA, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the
Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a
Multicenter Cohort Study. Antimicrob Agents Chemother. 2023. 67(8):e0040523.
11
12
13
77. Shah S, et al. Rates of Resistance to Ceftazidime-Avibactam and CeftolozaneTazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa
Bacteremia or Pneumonia. Clin Infect Dis. 2025. 80(1):24-28.
14
15
16
17
78. Lodise TP, et al. Comparative evaluation of early treatment with ceftolozane/tazobactam
versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to
multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024.
79(11):2954-2964.
18
19
20
79. Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for
acquired resistance. Clin Microbiol Infect. 2012. 18(3):268-281.
21
22
23
24
25
26
80. Hong LT, et al. International consensus recommendations for the use of prolongedinfusion β-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy,
British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European
Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of
America, Society of Critical Care Medicine, and Society of Infectious Diseases
Pharmacists. Pharmacotherapy. 2023. 43(8):740-777.
27
28
29
30
81. Gill CM, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in NonCarbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa:
Implications for Dose Optimization. Antimicrob Agents Chemother. 2021.
65(11):e0120421.
31
32
33
82. Bauer KA, et al. Extended-infusion cefepime reduces mortality in patients with
Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013.57(7):29072912.
34
35
36
83. Lodise TP, et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical
implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007. 44(3):357363.
37
38
84. Ramsey C, et al. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother 2016. 71:2704-12.
39
40
41
85. Scully BE, et al. Use of aztreonam in the treatment of serious infections due to
multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med.
1985. 78(2):251-261.
42
43
44
86. Moriyama B, et al. High-dose continuous infusion β-lactam antibiotics for the treatment
of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann
Pharmacother. 2010. 44(5):929-935.
45
46
87. Zhao L, et al. Development of in vitro resistance to fluoroquinolones in Pseudomonas
aeruginosa. Antimicrob Resist Infect Control. 2020. 9(1):124.
93
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
74. Shields RK, et al. Effectiveness of ceftazidime-avibactam versus ceftolozanetazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA
(CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025.
25(5):574-584.
5
6
7
75. Hareza DA, et al. Clinical outcomes and emergence of resistance of Pseudomonas
aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidimeavibactam. Antimicrob Agents Chemother. 2024. 68(10):e0090724.
8
9
10
76. Almangour TA, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the
Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a
Multicenter Cohort Study. Antimicrob Agents Chemother. 2023. 67(8):e0040523.
11
12
13
77. Shah S, et al. Rates of Resistance to Ceftazidime-Avibactam and CeftolozaneTazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa
Bacteremia or Pneumonia. Clin Infect Dis. 2025. 80(1):24-28.
14
15
16
17
78. Lodise TP, et al. Comparative evaluation of early treatment with ceftolozane/tazobactam
versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to
multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2024.
79(11):2954-2964.
18
19
20
79. Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for
acquired resistance. Clin Microbiol Infect. 2012. 18(3):268-281.
21
22
23
24
25
26
80. Hong LT, et al. International consensus recommendations for the use of prolongedinfusion β-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy,
British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European
Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of
America, Society of Critical Care Medicine, and Society of Infectious Diseases
Pharmacists. Pharmacotherapy. 2023. 43(8):740-777.
27
28
29
30
81. Gill CM, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in NonCarbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa:
Implications for Dose Optimization. Antimicrob Agents Chemother. 2021.
65(11):e0120421.
31
32
33
82. Bauer KA, et al. Extended-infusion cefepime reduces mortality in patients with
Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013.57(7):29072912.
34
35
36
83. Lodise TP, et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical
implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007. 44(3):357363.
37
38
84. Ramsey C, et al. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother 2016. 71:2704-12.
39
40
41
85. Scully BE, et al. Use of aztreonam in the treatment of serious infections due to
multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med.
1985. 78(2):251-261.
42
43
44
86. Moriyama B, et al. High-dose continuous infusion β-lactam antibiotics for the treatment
of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann
Pharmacother. 2010. 44(5):929-935.
45
46
87. Zhao L, et al. Development of in vitro resistance to fluoroquinolones in Pseudomonas
aeruginosa. Antimicrob Resist Infect Control. 2020. 9(1):124.
93